LifeMD reported second quarter revenue of $47.3 million, a 4% decrease from the prior year, and a loss per share of $0.16. The results were impacted by the company's ongoing transition to branded GLP-1 therapies, which affected near-term profitability. In response, LifeMD lowered its full-year 2026 guidance for both revenue and adjusted EBITDA.
Key Highlights
- Total active subscribers increased 20% year-over-year to approximately 356,000, with Weight Management Program subscribers growing to about 108,000.
- Gross margin expanded to 89% from 86% in the prior-year period, driven by lower fulfillment costs and scaling of the company's in-house pharmacy.
- Full-year 2026 revenue guidance was lowered to a range of $205.5 million to $212.5 million, from a previous range of $220 million to $230 million.
- Full-year 2026 adjusted EBITDA guidance was revised down to between a $6.0 million loss and breakeven, from previous guidance of $12 million to $17 million in profit.